Clinical Research Directory
Browse clinical research sites, groups, and studies.
Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy
Sponsor: EG 427
Summary
The aim of this study is to continue following participants who have received EG110A during five years to know how it is tolerated in humans, any side-effects it may cause and what might be an effective dose over five years. All participants who have received at least one dose/injection of EG110A in a previous clinical study of EG110A will be asked to roll-over to this long-term follow-up study upon either early discontinuation from, or completion of, that study.
Official title: Long-term Follow-up Study of Patients Who Received EG110A, a Non-replicative Herpes Simplex Virus 1-derived Gene Therapy Expressing a Transgene Encoding the Light Chain of Botulinum Toxin F
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
16
Start Date
2026-04
Completion Date
2031-04
Last Updated
2025-11-12
Healthy Volunteers
No
Interventions
Urodynamics
standardized local evaluation of urodynamic parameters
EG110A
Patients already treated with EG110A
Patient-reported Outcome
assessment of participant's perception of the level of impairment in functioning and well-being associated with NDO symptoms
Locations (4)
Rancho Los Amigos National Rehabilitation Center
Downey, California, United States
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, United States
Sidney Kimmel Medical College
Philadelphia, Pennsylvania, United States
UTHealth Houston / TIRR Memorial Hermann
Houston, Texas, United States